Persistent Asset Partners’s Cytokinetics CYTK Stock Holding History

Persistent Asset Partners’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$197K	Buy	+231	New	+$14.7K	0.07%	194

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Persistent Asset Partners's CYTK Position: Q1 2026 in Review

Persistent Asset Partners sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 3,214 shares — an estimated $204K sold.

Persistent Asset Partners first reported a position in CYTK in Q1 2025 and held it in 2 quarters. The position peaked at $204K in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Persistent Asset Partners reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
Persistent Asset Partners sold 3,214 Cytokinetics shares in Q1 2026, an estimated $204K.
Persistent Asset Partners first reported a position in Cytokinetics in Q1 2025 and held it in 2 quarters.
Persistent Asset Partners's Cytokinetics position peaked at $204K in Q4 2025.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.